Plasbumin-25 Market Report 2026

Plasbumin-25 Market Overview

• The Plasbumin-25 market growth in the historic period has been driven by established use in shock and hypovolemia, growth of critical care medicine • Market expansion is supported by rising liver disease incidence, increasing icu admissions • Growth Driver: Rising Liver Diseases Fuel Growth Of The Plasbumin-25 Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Plasbumin-25 Market?

Plasbumin-25 is a brand of human albumin solution, used primarily to restore blood volume and maintain plasma colloid osmotic pressure in patients with conditions like hypovolemia, burns, or liver cirrhosis. It helps in managing fluid balance during surgeries or in severe health conditions such as acute liver failure or shock. The 25% concentration allows for the effective treatment of hypoalbuminemia and supports critical functions in patients who experience protein loss or fluid imbalances. The main types of packaging sizes in plasbumin-25 are 50 mL, 250 mL, and 500 mL. The 50 mL packaging size is typically used in hospitals or clinical settings for patients with moderate needs or in emergency care. It offers a small, convenient dosage for short-term treatments. The indications include hypovolemic shock, hypoproteinemia, acute respiratory distress syndrome (ARDS), cardiopulmonary bypass, and acute liver failure with distribution channels such as hospitals and clinics, retail pharmacies, and specialty pharmacies. The end users include adult patients and geriatric patients.

What Is The Plasbumin-25 Market Growth Forecast?

The growth in the forecast period can be attributed to rising liver disease incidence, increasing icu admissions, growth in burn and trauma cases, expansion of hospital infrastructure, steady demand for plasma proteins. Major trends in the forecast period include high use of concentrated albumin solutions, rising demand in critical care management, preference for volume expansion therapies, growth in surgical and icu applications, continued reliance on plasma derived proteins.

Global Plasbumin-25 Market Segmentation

1) By Packaging Size: 50 mL, 250 mL, 500 mL 2) By Indication: Hypovolemic Shock, Hypoproteinemia, Acute Respiratory Distress Syndrome (ARDS), Cardiopulmonary Bypass, Acute Liver Failure 3) By Distribution Channel: Hospitals And Clinics, Retail And Specialty Pharmacies 4) By End User: Adult Patients, Geriatric Patients

What Are The Drivers Of The Plasbumin-25 Market?

The rising prevalence of liver disorders is expected to propel the growth of the plasbumin-25 market going forward. Liver disorders refer to a range of conditions that affect the liver's ability to function properly, including diseases like cirrhosis, hepatitis, fatty liver disease, and liver cancer. The incidence of liver disorders is increasing due to factors such as rising rates of alcohol consumption, obesity, diabetes, and viral infections such as hepatitis. Plasbumin-25 is used in liver diseases to restore albumin levels in conditions such as cirrhosis, hepatic failure, and ascites, helping manage fluid balance and prevent complications. For instance, in April 2024, according to the Office for Health Improvement and Disparities, a UK-based government body focused on addressing health inequalities, hospital admissions for liver disease in England rose to 85,665, corresponding to a directly standardized rate of 155.2 per 100,000 population, marking an increase compared with previous years. Admissions due to alcoholic liver disease alone totaled 27,085, highlighting a continued rise in alcohol-related liver complications. Therefore, the rising prevalence of liver disorders is driving the growth of the plasbumin-25 industry. The increasing number of road fatalities is expected to propel the growth of the plasbumin-25 market going forward. Road fatalities refer to deaths that occur as a direct result of injuries sustained in traffic accidents or road-related incidents. The increase in road fatalities can be attributed to factors such as higher vehicle speeds, distracted driving due to mobile phone usage, and insufficient road safety measures. Additionally, growing urbanization and the rising number of vehicles on the road contribute to more frequent and severe traffic accidents. Plasbumin-25 is frequently used to treat hypovolemic shock resulting from accidents such as car crashes, severe burns, or trauma, where significant blood or fluid loss occurs. For instance, in February 2023, according to a report published by Statistisches Bundesamt, a Germany-based federal statistical authority, approximately 21,600 individuals were injured in road traffic in 2023, an increase of around 900 injuries, or 5%, compared to 2022. Additionally, the number of fatalities in traffic accidents rose by 13, totaling 167 in February 2023. Therefore, the increasing number of road fatalities will drive plasbumin-25 industry. The growing healthcare spending is expected to propel the growth of the plasbumin-25 market going forward. Healthcare spending refers to the total expenditure on medical goods, services, insurance, and health-related activities within an economy. Healthcare spending is increasing primarily due to enhanced insurance coverage and expanded access to medical services, as higher insurance enrollment rates lead to greater utilization of healthcare facilities, treatments, and medications. This rise in healthcare expenditure directly increases the demand for albumin-based therapies like Plasbumin-25, which are essential for treating critical medical conditions in hospital and clinical settings. For instance, in November 2023, according to the Canadian Institute for Health Information, a Canada-based Institute for Health Information, in 2023, total health spending in Canada is projected to reach $344 billion, equating to $8,740 per person. This marks a 2.8% increase compared to the previous year, which saw only a 1.5% growth in health spending in 2022, indicating a notable rebound in healthcare investment. Therefore, growing healthcare spending is driving the growth of the Plasbumin-25 industry.

Key Players In The Global Plasbumin-25 Market

Major companies operating in the plasbumin-25 market are Grifols S.A.

Regional Insights

North America was the largest region in the plasbumin-25 market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Plasbumin-25 Market?

The plasbumin-25 market consists of sales of products including albumin solutions, immunoglobulins, clotting factors, and plasma-derived therapies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Plasbumin-25 Market Report 2026?

The plasbumin-25 market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the plasbumin-25 industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.